Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

Drug Resistant Epilepsy Clinical Trial

— LIFUS  

Official title:

Low Intensity Focused Ultrasound Treatment for Epilepsy: A Pilot Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03868293
• Other study ID #: 2018P000125
• Status: Recruiting
• Phase: N/A
• Start date: February 7, 2019
• Est. completion date: November 9, 2025

Study information

• Verified date: November 2023
• Source: Brigham and Women's Hospital
• Contact: Ellen J Bubrick, MD
• Phone: 617-732-7432
• Email: ebubrick[@]bwh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

Description:

The aim of the proposed pilot study is to investigate safety and tolerability of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

Due to the lack of options for patients with drug-resistant epilepsy, investigations into alternative noninvasive treatments are warranted. PLIFUS has been shown to safely modulate neuronal tissue, and is non-invasive and painless. Several human studies have shown that the use of PLIFUS can suppress somatosensory evoked potentials and induce functional magnetic resonance imaging (MRI) responses.

Once the subject is enrolled in the study, the subject will be scheduled for a standard brain MRI scan at BWH if they have not had one in the last 3 months. The subject will be asked to keep track of their seizure events in the Daily Seizure Log Diary from the screening visit until 6 months after the last treatment session.

The treatment period will include 6 treatment sessions total. These will occur 2 days per week for 3 weeks, each lasting approximately 1-2 hours, starting 1 month after seizure logging begins.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: November 9, 2025
• Est. primary completion date: November 9, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects at least eighteen (18) years of age

• Subjects with drug-resistant temporal lobe epilepsy whose seizures involve altered awareness (ie failed at least two trials of antiepileptic drugs for seizures), as determined by one of the BWH epilepsy neurologists based on clinical seizure semiology and/or EEG findings.

• Subjects who experience at least 1-2 seizures per month on average, are aware of or have reliable caregivers who are aware of when seizures occur and can reliably log seizure frequency

• Subjects who have the cognitive ability to read and understand the consent form, describe any potential symptoms experienced during or after treatments.

Exclusion Criteria:

• Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with testing

• Subjects with dementia or other progressive degenerative disease, delirium or active psychosis

• Subjects with ferromagnetic materials in the head

• Subjects with severe cardiac disease, increased intracranial pressure, or a Transcutaneous Electrical Nerve Stimulation (TENS) unit

• Subjects who have primary generalized epilepsy or non-epileptic seizures

• Subjects who have experienced status epilepticus in the 3 months leading up to enrollment in the study

• Subjects (females) who are pregnant, or are of childbearing potential and not willing to use reliable birth control during the treatment period.

• Subjects who are unable to get a brain MRI for any reason (implanted metal in body, inability to lie still)

• Subjects with current brain tumors or an intracranial vascular lesion

• Subjects with severe, uncontrolled medical problems, such as diabetes mellitus, hypertension, pulmonary or airway disease, heart failure, coronary artery disease, or any other condition that poses a risk for the subject during participation.

• Subjects with holes in the treatment area of the skull from trauma or prior surgery

• Subjects with pacemakers, medication pumps, and other implanted electronic hardware. If a subject has a working Vagal Nerve Stimulator in place, the device will be turned off prior to each treatment session and then turned back on after each session.

Related Conditions & MeSH terms

• Drug Resistant Epilepsy
• Epilepsy

Intervention

Device:
• Focused ultrasound
Pulsed low intensity focused ultrasound

Locations

Country	Name	City	State
United States	Brigham and women's Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bubrick EJ, McDannold NJ, White PJ. Low Intensity Focused Ultrasound for Epilepsy- A New Approach to Neuromodulation. Epilepsy Curr. 2022 Mar 29;22(3):156-160. doi: 10.1177/15357597221086111. eCollection 2022 Jun. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient tolerability of moderate term, repeated exposure toPulsed Low-Intensity Focused Ultrasound (PLIFUS) (Adverse Events assessment)	The aim of the proposed pilot study is to investigate patient tolerability of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy. We hypothesize that the treatments will be well-tolerated, without adverse events.	3 months
Primary	Efficacy of PLIFUS in reducing seizure frequency	The aim of the proposed pilot study is to investigate patient efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy .We hypothesize that PLIFUS stimulation will result in mechanical disruption of the target tissue (here, the epileptogenic focus), preserving the integrity of the tissue but rendering it unable (or less able) to mount seizure activity for a period of time.; We, therefore, will assess improvement in subjects' seizure frequency by evaluating seizure frequency during and 30 days after the treatment period relative to a 30 day pre-treatment baseline period.	3 months
Primary	Effect of PLIFUS on patient EEG (evaluate number of attenuated epileptiform discharges)	We hypothesize that subjects' EEGs will show improvement (fewer and/or attenuated epileptiform discharges). Study Epileptologists (either the PI or Co-I) will interpret EEG results during the first and last treatment session.	3 months